Lancet to Create Educational Communication Platform for Orphan Diseases


К списку новостей

Lancet to Create Educational Communication Platform for Orphan Diseases

On February 29, 2020 the world celebrated an international Rare (orphan) Disease Day to raise public awareness of this important issue affecting millions of people. This day has become official thanks to EURORDIS — European Organisation for Rare Diseases.

Worldwide, over 7,000 rare diseases have been registered affecting up to 8 % of the world population. Neglected etiologies, difficulty of diagnostics and treatment as well as development of promising practices and means require joint efforts of scientific and medical communities together with public authorities to establish a systematic approach towards research, prevention, early diagnostics, medical and social aid to patients with rare pathologies.

Orphan diseases represent one of the top priorities for SC Lancet. According to international trends in medicine and pharmaceutical business, the company focuses on innovative approaches to diagnostics and treatment of interstitial lung diseases: idiopathic pulmonary fibrosis — a rare disease of unknown origin, idiopathic and other forms of pulmonary arterial hypertension, L1 antitrypsin deficiency, and spinal muscular atrophy.

SC Lancet interacts with leading manufacturers around the world to promote novel treatments of orphan diseases in Russia. The company partners with the Russian Respiratory Society and takes part in organising scientific events, developing contacts with medical society in different regions of Russia and abroad.

An important step to implement the promotion strategies is to organise international interdisciplinary scientific events. Engagement of leading Russian and foreign scientific industry leaders in educational events enables Russian doctors to improve their skills and gain new knowledge in specific methods of diagnostics and treatment. Lancet encourages experts in bronchoscopy and cryobiopsy — the method used in complex cases of interstitial lung disease diagnostics — to take part in medical conferences. Doctors also gain valuable experience in sessions where complicated clinical cases are examined.

In 2019 such cross-functional educational events were held in Moscow, Vladivostok, Krasnodar, Novosibirsk, Krasnoyarsk, and Kazan.

According to the Managing Director of SC Lancet, Anton Olegovich Zybin, the company aims to provide a platform for information exchange and collaboration between scientific and medical societies as well as healthcare authorities in order to further investigate this global challenge and implement modern methods of diagnostics and treatment protocols for rare diseases into healthcare practices and to increase patient accessibility of high-quality medical care and novel medications.